Management of patients at very high risk of osteoporotic fractures through sequential treatments

Elizabeth M. Curtis1 · Jean-Yves Reginster2,3 · Nasser Al-Daghri4 · Emmanuel Biver5 · Maria Luisa Brandi6 · Etienne Cavalier7 · Peyman Hadji8,9 · Philippe Halbout10 · Nicholas C. Harvey1,11 · Mickaël Hiligsmann12 · M. Kassim Javaid13 · John A. Kanis14,15 · Jean-Marc Kaufman16 · Olivier Lamy17 · Radmila Matijevic18,19 · Adolfo Diez Perez20 · Régis Pierre Radermecker21 · Mário Miguel Rosa22 · Thierry Thomas23,24 · Friederike Thomasius8 · Mila Vlaskovska25 · René Rizzoli5 · Cyrus Cooper1,11,26

Received: 11 February 2022 / Accepted: 18 February 2022 / Published online: 24 March 2022 © The Author(s) 2022

Abstract
Osteoporosis care has evolved markedly over the last 50 years, such that there are now an established clinical definition, validated methods of fracture risk assessment and a range of effective pharmacological agents. Currently, bone-forming (anabolic) agents, in many countries, are used in those patients who have continued to lose bone mineral density (BMD), patients with multiple subsequent fractures or those who have fractured despite treatment with antiresorptive agents. However, head-to-head data suggest that anabolic agents have greater rapidity and efficacy for fracture risk reduction than do antiresorptive therapies. The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) convened an expert working group to discuss the tools available to identify patients at high risk of fracture, review the evidence for the use of anabolic agents as the initial intervention in patients at highest risk of fracture and consider the sequence of therapy following their use. This position paper sets out the findings of the group and the consequent recommendations. The key conclusion is that the current evidence base supports an “anabolic first” approach in patients found to be at very high risk of fracture, followed by maintenance therapy using an antiresorptive agent, and with the subsequent need for antiosteoporosis therapy addressed over a lifetime horizon.

Keywords Osteoporosis · Epidemiology · Imminent · Fracture · Anabolic · Antiresorptive

Introduction
Osteoporosis presents a massive, and inexorably increasing, burden on health and social care, at the levels of patients, healthcare providers and policymakers [1–5]. Osteoporotic fractures are associated with reduced quality of life and significant morbidity, mortality and utilisation of healthcare resources [4]. Between 2010 and 2040, the number of individuals at high risk of fracture is predicted to double worldwide, with the largest increases (relative increases of twofold or greater) expected in Africa, Latin America and Asia [6]. In Europe, the recent ScoreCard for OsteoPorosis in Europe (SCOPE) collaboration has estimated that by 2034, 5.34 million individuals will be affected by osteoporotic fractures in the European Union plus the UK and Switzerland (EU 27 + 2 countries), an increase of 1.06 million (24.8%) from 2019 [4].

Despite the fact that osteoporosis is a well-recognised problem with a choice of affordable and widely available treatments (particularly for the health economies of high-income countries), a large treatment gap exists. In the EU27 + 2, 71% of women (15 of 21 million) likely to warrant treatment for osteoporosis are left without appropriate medication [4]. An International Osteoporosis Foundation report suggested that this was due to a variety of challenges in case finding and management, a lack of public awareness (including misconceptions regarding the benefit–risk balance of treatment), and government and health system issues (such as difficulty in accessing reimbursement for osteoporosis treatments, and lack of prioritisation of fracture prevention in national health policy) [7].
Whilst there is clearly a major issue with treating patients at all, there is also increasing evidence to suggest that stratification of treatment according to baseline fracture risk may permit targeting of the most effective treatments to patients at the highest fracture risk [8]. Such a strategy would ensure greatest rates of fracture risk reduction in those most likely to fracture and thus contribute to addressing the current treatment gap as well as maximising benefits for the most vulnerable individuals. Some treatments for osteoporosis, for example oral bisphosphonates, menopausal hormonal therapy (MHT) and selective oestrogen receptor modulators (SERMs) have suboptimal efficacy; studies of goal-directed treatment in osteoporosis have highlighted difficulties in meeting treatment goals with such therapies in the highest fracture risk patients [9]. Consequently, the IOF and European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) published guidance for the diagnosis and management of osteoporosis in 2019, with subsequent recommendations on treatment stratification in 2020 [10], stating that, in patients at the highest risk of fracture, treatment initiation with an anabolic (bone-forming) agent such as teriparatide, abaloparatide or romosozumab, followed by an antiresorptive to maintain the gains in bone mineral density, appears now a highly appropriate strategy to achieve a rapid and sustained reduction in fracture risk [11, 12]. This recommendation has strong evidential support from recent studies comparing anabolic with antiresorptive medications, demonstrating a more rapid and greater fracture risk reduction with the former, compared with antiresorptive treatments alone [13–16].

Implementation of such guidance, however, presents some challenges: How should a patient at very high fracture risk be identified? Which anabolic drug should be chosen (and likely not just on the basis of efficacy and clinical profile, but dependent upon local licensing and reimbursement considerations)? What should be the duration of anabolic therapy, and what should be the duration of subsequent antiresorptive therapy? Can a patient be cycled between anabolic and antiresorptive treatment multiple times? Is sequential therapy with an anabolic first a cost-effective way of allocating resources?

To address these questions, a working group convened by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) met to review current data on these topics. The group comprised 25 experts from 13 countries with expertise covering osteoporosis, rheumatology, geriatrics, clinical chemistry, epidemiology, public health, health services research, health economics and drug safety. This consensus report summarises the working group’s assimilation of the current literature and consequent recommendations regarding strategies for the identification and sequential treatment, through anabolic and antiresorptive medications, of patients at very high fracture risk.

Approaches to risk stratification

Introduction

Several approaches have been developed with which to identify individuals at very high fracture risk. These range from criteria based on clinical scenarios, to predictive algorithms derived using population registries, for example with machine learning techniques, and modifications to existing algorithms such as the FRAX® fracture risk assessment calculator. An important nuance in the interpretation of the outputs from such methods is that of the time horizon considered [17]. The concept of “imminent” fracture risk has been discussed increasingly widely but has a variety of meanings in different contexts. For example, several studies have examined predictors of risk over a subsequent two-year period with the inference that these predict a fracture risk which is “imminent” given the short time horizon [18]. However, as will be discussed below, there are only a minority of clinical risk factors which raise fracture risk in the short much more than in the long-term. Recent prior fracture and supraphysiologic corticosteroid treatment are examples, but risk factors associated with higher short-term risk are usually also associated with high long-term risk [17]. A second characterisation of “imminent fracture risk” is that directly linked to the transient markedly increased risk of a subsequent fracture immediately after an index event [19]. This will be discussed in more detail in the section on the FRAX tool below and represents one route into a very high fracture risk, alongside other combinations of risk factors.

Cohort-derived methods

Different audiences, for example, policy makers undertaking evaluation of expensive new antiosteoporosis therapies; clinicians deciding which patients are at very high risk and are suitable for the most potent treatments and tightest monitoring; and patients considering whether or not they wish to take an antiosteoporosis medication, are likely to require different characteristics in an assessment of fracture risk. Policy makers may prefer accurate, complicated (requiring large volumes of input data), evidence-based models; clinicians require validity for their individual patient, with readily available inputs and easily actionable outputs; patients may prefer personalised, short-term outcomes, which are relatable to other health and lifestyle-related risks to help inform decision-making.
Aside from FRAX (discussed in more detail below), other cohort-derived risk calculators are available, including Q-Fracture (https://qfracture.org/) and Garvan (https://www.garvan.org.au/promotions/bone-fracture-risk/calculator/) fracture risk calculators [20–22]. Q-Fracture, though not widely used, is integrated into some Primary Care patient management systems in the UK and allows one to alter the duration of risk, from 2 years, to 5 years, to 10 years, apparently using a simple arithmetic approach. Garvan provides the option for a 5-year risk output, though again this is just half the calculated 10-year risk—as discussed previously, imminent fracture risk is important and there is not a linear accrual of fractures over a 10-year timeframe, with fracture risk much higher in the first two years post an index fracture event than over the remaining eight years of a 10-year time horizon [19].

Multi-cohort approaches have been used more recently, aiming to characterise 1- to 2-year fracture risk. A study led by Prieto-Alhambra et al. used primary care data in patients at high fracture risk from the UK Clinical Practice Research Datalink (CPRD) \( (n = 83,000 \text{ linked to Hospital Episode Statistics in England}) \), the Catalonian Information System for Research in Primary Care (SIDIAP) \( (n = 51,000, \text{ linked to regional hospital data}) \), and the Danish Health Registry (DHR) \( (n = 509,000) \) (linked to the Danish national register of diagnostic codes for all inpatients and outpatients). The authors were able to demonstrate that individuals with an incident fracture (at any site, excluding the skull, face or digits) were at increased risk of subsequent hip, clinical spine, humerus or distal forearm fractures (major osteoporotic fractures), with a 2-year incidence rate per 10,000 person-years of 22.0 (95% CI 21.2–22.8) in the UK CPRD; 24.0 (95% CI 23.0–25.0) in Spain (SIDIAP); and 36.9 (36.5–37.3) in Denmark (DHR). Such differences between countries may be explained by data collection methods as well as true differences in population level fracture risk [23]. The study also examined major osteoporotic fracture risk after index hip fracture at 1-year follow-up in men and women aged over 50 years; incidence rates were low, however, and provided a 1-year risk of around 2% in CPRD/SIDIAP and 5% in DHR [24]. The incident fragility fracture prediction model (in which the model parameters are freely available) demonstrated good performance for hip fracture at 1 year in Spain, Denmark and the UK, and calibration was good across all three countries, with the authors concluding that such imminent fracture risk prediction models could be used to precisely identify patients at high imminent risk of fracture, thereby informing antosteoporosis treatment selection [25].

In a Dutch study of 4140 postmenopausal women with a known fracture history, after a first fracture 23% of all subsequent fractures occurred within 1 year and 54% within 5 years. When calculated from time of first fracture, the relative risk (RR) of subsequent fracture was 2.1 (95% CI 1.7–2.6) and remained increased over 15 years. This study demonstrated elevated imminent fracture risk, as, when calculated for specific time intervals after a first fracture, the RR was 5.3 (95% CI 4.0–6.6) within 1 year, 2.8 (95% CI 2.0–3.6) within 2–5 years, 1.4 (95% CI 1.0–1.8) within 6–10 years and 0.41 (95% CI 0.29–0.53) after >10 years [26].

The Swedish national patient register has also been used to evaluate the cumulative incidence of new fractures. In a study of 35,146 women with a mean age of 73.8 years and an index fracture in 2013, cumulative incidence of a new fracture over 2 years was 11%, with fracture location influencing the incidence and type of subsequent fracture. The risk of second fracture was highest in index clinical vertebral (18%) and hip fractures (14%), and despite high re-fracture rates, low treatment rates were observed across all fracture types and age groups [27]. Using a similar design, amongst insurance scheme registrants in Germany with an index fracture of the hip, vertebra, forearm or upper arm (18,354 male and female patients, mean age 77 years), 15% sustained a subsequent fracture during a shorter, 1-year follow-up period, with those with an index vertebral fracture again being at highest risk (18%) and highlighted as a group for urgent antosteoporosis treatment [28].

### Machine learning approaches

A novel approach to the identification of patients at high fracture risk over a short time frame uses machine learning technology, applying deep learning to sequential patient data. Crystal Bone is a machine learning approach using longitudinal data contained in electronic health records, and was developed using subsets of the United States’ Optum (UnitedHealth Group) deidentified electronic health data record set covering 91 million patients from over 140,000 providers, from which patients with osteoporosis, fractures or bone related medications were included [29]. Using data from over 1 million patients, the Crystal Bone algorithm was developed, leveraging techniques typically applied in natural language processing (to understand large volumes of textual data), focusing on International Classification of Diseases (ICD) codes (Fig. 1). The goal was to evaluate the ability of these language processing-based models to learn patterns associated with increased 2-year fracture risk. The model was shown to accurately predict 1–2-year fracture risk for patients aged over 50 years, with an area under the receiver-operating characteristics curve (AUROC) 0.81, representing an improvement over baseline models and FRAX 10-year risk, though the authors acknowledged that direct comparisons cannot be made. Similarly, the Danish Fracture Risk Evaluation Model (FREM) aimed to identify...
conditions for inclusion in a fracture prediction model for automated case finding of high risk individuals for hip or major osteoporotic fracture (MOF). The whole of the Danish population aged over 45 years was studied (almost 2.5 million individuals), incorporating all hospital diagnoses from 1998 to 2012 with MOFs in 2013 as the primary outcome. Backward selection on ICD-10 codes (International Classification of Diseases and Related Health Problems, 10th Revision) by logistic regression was used to develop an age-adjusted and sex-stratified model in development and validation datasets. The FREM included 38 and 43 risk factors for MOF in women and men, respectively, and produced receiver-operating characteristic (ROC) curves with an area under the ROC curve (AUC) of 0.750 (95% CI 0.741–0.795) and 0.752 (95% CI 0.743–0.761) for women and men, demonstrating good accuracy, with even higher accuracy demonstrated for hip fractures [30]. The model has also recently been shown to generate similar results when using a 5-year look-back as opposed to applying data from a 15-year period, implying it may be applied to improved identification of individuals at high imminent risk of fracture [31].

Clearly, there may be problems in applying these findings to other populations due to lack of generalisability of both the patient population and the available variables, and questions arise as to how these approaches can be implemented in other countries. The Danish FREM algorithm, for example, significantly overestimated hip fracture risk when applied to an independent clinical population from Manitoba, Canada, indicating the need for recalibration [32]. However, in healthcare systems where such rich data and machine learning technologies are available, this approach may indeed be a practicable future direction of travel, and could help with the identification of patients at very high risk of fracture, perhaps as a first population level healthcare provider “screen” for those who might warrant further assessment.
Expert consensus around clinical scenarios and/or BMD represents another route to the definition of very high fracture risk and of imminent fracture risk. Whilst the ESCEO and the IOF, in the European guidelines, recommend FRAX-based approaches, as previously described [11, 12, 10], the US Endocrine Society use a prior fracture and T-score based approach, defining very high risk as an individual with multiple spine fractures and a T-score of $\leq -2.5$ [33]. The UK Scottish SIGN guidelines employ a similar approach, defining severe osteoporosis as the presence of 1 severe or 2 or more moderate vertebral fractures with a T-score of $\leq -1.5$, or a lumbar spine T-score of $\leq -4$, irrespective of fracture [34].

Consistent with the recent ESCEO-IOF and UK NOGG approaches [35], Swiss guidelines define very high fracture risk as when an individual’s 10-year probability of major osteoporotic fracture according to FRAX is at least 20% ($1.2 \times$) above the absolute risk intervention threshold at any age. High imminent risk is defined as 10% within 2 years, characterised by an age threshold of 65 years or older, and a prior fracture of major osteoporotic fracture (hip, clinical vertebral fracture, humerus, pelvis or radius) [36]. Recent operational guidance in the UK has taken a similar approach but with a 10-year time horizon suggesting that very high fracture risk, incorporating the notion of high imminent risk in the shorter term, may be captured by the presence of a recent fracture and a 10-year FRAX major osteoporotic fracture probability of 30% more [37].

Many similarities and many differences are present within these expert consensus guidelines. All agree that recent fractures should be defined as within the past 2 years. They differ by the use of DXA T-scores in some, versus FRAX thresholds in others (which may be fixed, or age related), and they also differ in their definitions of major osteoporotic fracture. Some include the distal forearm and some do not; such inconsistencies in expert recommendations may not help the osteoporosis field in general, supporting the need for a more unified approach.

**FRAX and imminent fracture risk**

The FRAX fracture risk assessment tool, in use since 2008, integrates information on 10 different clinical risk factors, with or without BMD measurement, generating 10-year probabilities for major osteoporotic fracture (hip, clinical vertebral, proximal humerus and distal forearm) and for hip fracture (https://www.sheffield.ac.uk/FRAX/) [38]. The clinical risk factors were chosen on the basis of intuitive linkage to fracture risk and ready clinical availability following a series of meta-analyses of prospective cohort studies from Europe, North America, Asia and Australia including nearly 45,000 individuals, and have subsequently been validated in other cohorts. A unique feature of the FRAX algorithm is the integration of risk of death with risk of fracture, to yield a 10-year probability of fracture, which incorporates not just fracture risk, but also the competing hazard of death. At older ages where predicted survival is less than 10 years, the output fracture probability reflects a remaining lifetime horizon [39]. At the time of writing, 81 FRAX models are available in 73 countries covering around 80% of the world population, and the tool is used in over 100 guidelines worldwide [11, 40–42]. Thresholds have been devised in many countries to advise clinicians on when to prescribe antosteoporosis treatment (intervention thresholds) [41]. Given that most assessment guidelines recommend treatment in postmenopausal women with a prior fragility fracture, the European recommendations include age-dependent intervention thresholds which reflect the age-specific fracture probability equivalent to a woman of average BMI with a prior fragility fracture, no additional risk factors, and without knowledge of BMD [11]. In European countries (and indeed many others), around the intervention threshold, assessment of bone mineral density is recommended to determine whether a person lies above the threshold (at which point they would be recommended treatment) or below the threshold (at which point they would be recommended lifestyle advice) [11].

With the increasing evidence for more rapid and greater magnitude of therapeutic effect for anabolic agents compared with antiresorptives (discussed in more detail in the next section), the IOF and ESCEO have recommended that individuals eligible for treatment be dichotomised into those at high risk and those at very high risk of fracture [10]. In this way, patients at very high risk of fracture can be directed to the more expensive but more efficacious anabolic therapy first [13–16], whilst those at high risk can be directed to an antiresorptive agent such as a bisphosphonate (Fig. 2).

Consistent with the age-dependent approach to the intervention threshold, in the IOF-ESCEO approach, very high risk can be defined as a fracture probability that lies above the upper assessment threshold (1.2 times the intervention threshold) after a FRAX assessment, with or without the inclusion of BMD, i.e. where BMD testing is unavailable, the same probability threshold can be used [43]. A similar approach has been applied nationally in the UK National Osteoporosis Guideline Group recommendations [35], with the threshold adapted to incorporate the constant probability threshold above the age of 70 years in this hybrid setting [44]. The next question to address is what attributes and clinical risk factors are associated with FRAX probabilities in low, high and very high fracture risk categories. In this setting, it is apparent that the presence of a single clinical risk factor rarely leads to very high fracture risk.
categorisation but a combination of risk factors, particularly older age, recent fracture and glucocorticoid use, more frequently result in this high fracture risk outcome [35].

As introduced earlier in this article, the trajectory of risk associated with the recent prior fracture appears to be a particularly important, but by no means exclusive, contributor to very high fracture risk categorisation. To this end, several studies have demonstrated that fracture risk is acutely elevated immediately after an index fracture and that this elevated risk wanes over the succeeding 2 years (this transiently elevated risk also can be termed “imminent” risk), but does not return to baseline and subsequently increases with age [26, 46, 47]. Thus, a fracture at any time in the past is associated with increased risk of an incident fracture event, but an index fracture is associated with a marked excess fracture risk over and above this in the next 2 years [17, 19]. This pattern has been most comprehensively assessed in the Iceland Reykjavik cohort [19, 45], and further data from the Reykjavik Study have shown that, in individuals who sustained a recurrent fracture, between 31 and 45% of fractures occurred within one year of the first (sentinel) fracture, depending on the fracture site [19]. Further work using this cohort has demonstrated that the transient risk increase following an index fracture is of great enough magnitude to materially alter the 10-year probability of fracture generated by the FRAX tool [19]. Importantly, the currently available tool does not incorporate recency of fracture, or indeed a different risk associated with different fracture sites and therefore will underestimate 10-year fracture probability in the context of a prior fracture in the last 2 years. To address this situation, multipliers specific to age, sex and fracture site have been generated to enable the physician to accommodate the excess risk associated with recency and particular fracture types [48]. The multiplier decreases with age, partly because of the competing effect of mortality with which recency is also associated, but because fracture probability is so strongly dependent upon age, the final adjusted absolute probability is almost always greater at older compared with younger ages [48]. It is also apparent that the magnitude of the absolute fracture probability is always greater when viewed over a 10-year, than over a 2-year, time horizon [49]. Development of a platform enabling the easy incorporation of the multiplier as a modifier of the FRAX calculator online is ongoing and will be available as FRAXPLUS. A key advantage of this approach is that recency and site of fracture, along with other modifiers...
of FRAX probability, for example dose of glucocorticoids, can be used to modify FRAX probability in a way that is immediately interpretable in the context of current national guidelines which are based on 10-year FRAX probability. The limitation of calculators and algorithms estimating fracture risk over the next 2 years is that, at present, there is generally no guideline infrastructure through which the outputs can be directly incorporated into clinical practice and there are few data to support their generalisability into other country settings. On a practical note, the key message in terms of fracture recency is that a fracture event requires urgent assessment of fracture risk and intervention with anti-osteoporosis medications.

**Summary: fracture risk assessment**

In summary, it is apparent that there are several different mechanisms for the identification of individuals at very high risk of fracture. These differ in their approach with the majority addressing fracture risk over a 2-year time horizon, terming this concept “imminent” fracture risk. Importantly the majority of such studies have not compared the predictive value over 2 years with that over 10 years and as such, it is very likely that being identified as at high risk in the next 2 years confers high risk over the next 10 years and indeed over the remaining lifetime [17, 49]. The most thoroughly characterised approach is that using the FRAX calculator linked with age-dependent intervention thresholds to identify individuals at high and very high fracture risk [48]. Importantly, whatever method is used in whatever context, the goal is to identify individuals at very high fracture risk because the higher the fracture risk the more likely there will be a fracture in the next few years (i.e. the more imminent the risk) and the more urgent is the need for treatment which is highly effective and rapid acting. Having established the different ways in which individuals at very high fracture risk may be identified, in the next section, we address the potential approaches to anabolic first therapy.

**Approaches to sequential therapy**

**The anabolic first approach in very high fracture risk patients**

There is increasing evidence to suggest that the anabolic agents for osteoporosis, teriparatide, abaloparatide, and romosozumab are superior in efficacy, and rapidity of action, to the antiresorptive agents in their ability to increase bone mineral density and prevent fractures [13–16]; these benefits must be maintained, however, by following the anabolic with an antiresorptive drug [14, 50, 51]. Indeed, there is also evidence to suggest that the sequence of treatment given to a patient with osteoporosis is important, such that an anabolic agent given prior to an antiresorptive agent is more efficacious than the opposite sequence [52, 53]. Whether this observation is generalisable across all anabolics is currently unknown, but based on existing evidence and understanding of mechanisms of action, it is likely to hold. Such agents are given over a relatively short time interval of one to two years, but the fact that BMD can be maintained with an inhibitor of bone resorption is extremely important in terms of fracture risk reduction. If we take the example of an anabolic agent (in a hypothetical population) that reduced the hip fracture risk by 70% (relative risk reduction, RRR = 70%), the anabolic agent, given for 18 months, then followed by an antiresorptive to maintain the effect for a total of 10 years, might be expected to save 33.8 hip fractures/1000 patient years in women aged 70 years with a recent fragility fracture [15]. In contrast, an antiresorptive (in the same hypothetical population) that reduced the hip fracture risk by 40% (RRR = 40%) followed by an anabolic regimen for the last 18 months of a 10-year treatment would save only 20.0 hip fractures/1000 patient years [10]. This alters the paradigm for the use of anabolic therapies, going beyond their current widespread use as “salvage therapy” when all other treatment has failed, to the notion of first-line anabolic treatment. In turn, this new paradigm suggests the need for clinicians to be able to identify the individuals who would most benefit from an anabolic therapy. The evidence for the efficacy of bone-forming agents in terms of BMD gained and fractures prevented is summarised below.

**Teriparatide**

Teriparatide, recombinant human parathyroid hormone amino-terminal fragment, preferentially stimulates osteoblasts to produce new bone tissue, thereby increasing bone mass and strength [54] and has been shown to reduce vertebral and non-vertebral fractures in post-menopausal women with established osteoporosis at a daily dose of 20 µg/day SC [55]. The Fracture Prevention Trial in 2001 demonstrated the sustained effect of teriparatide in reducing the risk of non-vertebral fragility fractures after a median exposure of 19 months, and showed reversibility of the beneficial effects of teriparatide on femoral neck and hip BMD following discontinuation. Such declines in BMD were prevented by administration of a bisphosphonate and raloxifene after teriparatide treatment, and this response has been observed in both men and women with osteoporosis [57–60].

The VERO study of teriparatide vs risedronate in osteoporosis demonstrated the superiority of the anabolic over the antiresorptive agent in preventing fragility fractures. This was a double-blind, double-dummy trial of postmenopausal women with at least two moderate or one severe vertebral fracture and a BMD T-score ≤ − 1.5. Participants were
randomised to 20 µg teriparatide once daily SC plus oral weekly placebo or 35 mg oral risedronate once weekly plus daily injections of placebo for 24 months, with 680 patients in each group. The primary outcome was new radiographic vertebral fractures: at 24 months, new vertebral fractures occurred in 28 (5.4%) of 680 patients in the teriparatide group and 64 (12.0%) of 680 patients in the risedronate group (risk ratio 0.44, 95% CI 0.29–0.68; p < 0.0001). Clinical fractures (a composite of non-vertebral and symptomatic vertebral fractures) were also reduced (hazard ratio 0.48, 95% CI 0.32–0.74; p = 0.0009), no significant difference in non-vertebral fragility fractures was observed (Fig. 3). The authors concluded that clinicians should consider teriparatide for optimal management of patients with prevalent vertebral fractures—a well-defined high fracture risk group [13].

Teriparatide plus denosumab, and sequence of agents

Whilst studies combining teriparatide and bisphosphonates have reported no benefit compared to the anabolic agent alone [62, 63], the DATA study combined teriparatide and denosumab for a 24-month period and observed increases in BMD greater than either agent alone [64]. The DATA-Switch extension, in which postmenopausal osteoporotic women were assigned to 24 months of denosumab at the end of the study if they had received teriparatide (so creating a teriparatide to denosumab group), those assigned to denosumab received teriparatide (denosumab to teriparatide group) and those originally assigned to denosumab and teriparatide in combination received an additional 24 months of denosumab alone (combination to denosumab group). In this trial, switching from teriparatide to denosumab, bone mineral density continued to increase, whereas switching from denosumab to teriparatide resulted in progressive or transient bone loss (no fracture data are available) [65].

Abaloparatide

Abaloparatide is another osteoanabolic drug, also given by subcutaneous injection, designed to have a more rapid onset of action than teriparatide by the strategic insertion of residues into the PTH-related peptide amino-terminal fragment. The resulting peptide is a selective activator of the PTH type 1 receptor signalling pathway and has the ability to produce anabolic effects with modest stimulation of bone resorption in comparison with teriparatide [66]. The ACTIVE trial (Abaloparatide Comparator Trial In Vertebral Endpoints) indicated that abaloparatide treatment for 18 months reduced new morphometric vertebral fractures by 86% and non-vertebral fractures by 43% in comparison with placebo, with rapid separation in non-vertebral fracture risk between the abaloparatide and placebo groups [67].

In the ACTIVExtend trial (determining the efficacy and safety of 18 months of daily subcutaneous abaloparatide compared with placebo (the ACTIVE trial), followed by oral, open-label alendronate for an additional 24 months in...
women with postmenopausal osteoporosis), abaloparatide followed by alendronate improved bone mineral density and reduced fracture risk, compared with placebo followed by alendronate, with greater benefits the longer alendronate was given. For example, for non-vertebral fractures, the risk reduction was 52% (hazard ratio [HR], 0.48; 95% CI 0.26–0.89). There was also a 58% risk reduction of major osteoporotic fractures (HR 0.42; 95% CI 0.21–0.85) and a 45% risk reduction of clinical fractures (HR 0.55; 95% CI 0.33–0.92) in the abaloparatide followed by alendronate group vs the placebo followed by alendronate group [68], again indicating superiority of using anabolic agents first in sequence in comparison with antiresorptive drugs then anabolic salvage in fracture prevention.

Head to head studies of different PTH analogues are limited [67], however numbers needed to treat were calculated from the pivotal trial for both abaloparatide and teriparatide (as the reciprocal of the absolute risk reductions seen with each agent versus placebo, and clearly with the caveats of separate trial populations) [69]. In order to prevent one new vertebral fracture, 28 women would need to be treated with abaloparatide and 30 treated with teriparatide. To prevent one new non-vertebral fracture, 55 women would need to be treated with abaloparatide and 92 treated with teriparatide. Examining differences in the mechanisms of action and their comparative effectiveness in basic and clinical studies may further guide their clinical application in the future [70].

**Romosozumab**

With a completely different mechanism of action, romosozumab is a humanised monoclonal antibody that binds and inhibits sclerostin, and has the dual effect of increasing bone formation and decreasing bone resorption [71, 72]. The FRAME trial enrolled 7180 postmenopausal women between the ages of 55 and 90 years with osteoporosis defined by T-score ≤ − 2.5 at the spine, hip, or femoral neck [73]. Patients were randomised to subcutaneous injections of romosozumab (at a dose of 210 mg in 2 injections) or placebo monthly for 12 months; thereafter, patients in each group received denosumab for 12 months, at a dose of 60 mg, administered subcutaneously every 6 months. After 12 months, a 73% lower risk of vertebral fracture was observed with romosozumab; p < 0.001, and a 36% lower clinical fracture risk was seen (p = 0.008), but there was no significant difference in the non-vertebral fracture rate. At 24 months, following the transition to denosumab in both groups, the rate of vertebral fractures was 75% lower in the romosozumab group than in the placebo group (p < 0.001). In a post hoc analysis of the role of regional background fracture risk on non-vertebral fractures, risk reductions were not observed in Latin America, but romosozumab significantly reduced non-vertebral fracture risk in the rest of the world (42% reduction, p = 0.012) [74]. This is probably related to the low risk in these countries given the higher the basal fracture risk, the higher the efficacy of romosozumab [75].

The FRAME extension study demonstrated that one year of romosozumab followed by 2 years of denosumab (compared with 1 year of placebo followed by 2 years of denosumab) led to consistent reductions in fracture risk (new vertebral fracture (relative risk reduction [RRR], 66%; incidence, 1.0% versus 2.8%; p < 0.001), clinical fracture (RRR, 27%; incidence, 4.0% versus 5.5%; p = 0.004), and non-vertebral fracture (RRR, 21%; incidence, 3.9% versus 4.9%; p = 0.039) and ongoing BMD gains. At 36 months, in the group that received romosozumab followed by 2 years of denosumab, mean T-scores improved from − 2.7 to − 1.5 in the spine and from − 2.5 to − 2.0 in the total hip. The proportion of participants who had a T-score in the osteoporosis range decreased from 63% at baseline to 20% at 3 years in the spine and from 53 to 14% in the total hip [76].

In an analysis of treatment response, BMD gains of ≥ 6% in the spine were achieved by 68% of participants who received romosozumab versus 6% in those on placebo at the 1-year timepoint, and at the total hip, BMD gains of ≥ 6% were seen in 47% of romosozumab-treated versus 3% of placebo-treated patients; such BMD gains were reflected in lower fracture rates. The magnitude of the BMD gains was large in the romosozumab/denosumab treatment sequence; at 2 years such gains were similar to the BMD gains observed with 7 years of denosumab alone in the Freedom/Freedom Extension study [77, 78].

In the ARCH study, romosozumab was compared directly to the antiresorptive bisphosphonate, alendronate. 4093 women, age range 55–90 years, with prevalent osteoporotic fracture were enrolled and randomised to receive romosozumab 210 mg subcutaneously once monthly or alendronate 70 mg once weekly orally for 1 year in a double-blind fashion. All participants subsequently received open-label alendronate for the remainder of the study with a time-to-event design, which had a median treatment period of 2.7 years (33 months). Romosozumab followed by alendronate was more effective than alendronate in preventing vertebral fractures at 24 months, (risk ratio 0.52; incidence 6.2% versus 11.9%; p < 0.001), and clinical fractures at the time of primary analysis, co-primary endpoints (risk ratio 0.73; incidence 9.7% versus 13.0%; p < 0.001). In addition, the risk of non-vertebral fractures was lower by 19% in the romosozumab-to-alendronate group than in the alendronate-to-alendronate group (incidence 8.7% vs 10.6%; p = 0.04), and the risk of hip fracture was lower by 38% (incidence 2.0% vs. 3.2%; p = 0.02). Gains in BMD were substantially higher in patients who received romosozumab compared with alendronate in year 1. In the romosozumab group the BMD gains were very similar to those seen in FRAME.
the ARCH trial, BMD increased further after the transition to alendronate; however, the BMD gains at 36 months were not as impressive as those seen in FRAME when women transitioned from romosozumab to denosumab [14].

Reversal of the beneficial effects of romosozumab on cessation of therapy (2 years denosumab and switched to placebo), and prevention of BMD loss at the lumbar spine and hip by administration of denosumab was demonstrated by McClung et al. Women receiving romosozumab who transitioned to denosumab continued to accrue BMD, whereas BMD returned toward pretreatment levels with placebo [79]. McClung et al. also demonstrated that after a second course of romosozumab, administration of an anti-resorptive (intravenous zoledronate) also maintained the robust BMD gains observed with romosozumab treatment, though without anti-resorptive administration, such beneficial effects were lost [80].

It is of interest that the effects of romosozumab are greater the higher the fracture probability at baseline [75], a phenomenon which is not seen with teriparatide [81, 82]. This makes romosozumab of particular relevance in patients at very high fracture risk.

An important and as yet not completely resolved consideration with the use of romosozumab is the apparent increased risk of cardiovascular adverse outcomes in the treatment group in the ARCH trial. In post hoc analyses of the composite outcome of non-fatal MI, non-fatal stroke and cardiovascular death plus heart failure and non-coronary heart disease, the incidence was 2.0% in the romosozumab group and 1.1% in the alendronate group (HR 1.7, 95% CI 1.1–2.6). A similar signal was not seen in the FRAME trial and is currently subject to ongoing post marketing surveillance studies [83].

**Choice of anabolic agent**

The ESCEO working group agreed that it is difficult to differentiate between the available anabolic agents as head-to-head comparisons are limited to two studies [67, 84], hence such recommendations are outside the scope of this document. Therefore, recommendations apply to anabolics as a class rather than as individual agents.

An important consideration for the implementation of the recommendations made in this position paper, of “anabolic first” in patients at very high risk of fracture, is that the availability of any particular medication will likely be different by country and also potentially by healthcare providers within countries. For example, at the time of writing, teriparatide is widely available globally, whereas abaloparatide is not licensed in Europe. In the UK, whilst a medication may be licensed by the regulatory authorities, its use in the National Health Service may be further adjudicated by the National Institute for Health and Care Excellence (NICE). Historically, as with many healthcare systems, the available anabolic, teriparatide, was specifically positioned for those patients with severe osteoporosis who have failed other therapies or with multiple subsequent fractures; thus a paradigm change to initial treatment with anabolics will in many cases require alterations to national guidance. Reassuringly, continuing the example of the UK, the earlier shift from BMD to absolute fracture risk based on FRAX has demonstrated that clinician led guidance, through the UK National Osteoporosis Guideline Group (produced as a response to the impractical NICE approach) has subsequently become NICE accredited and incorporated into NICE quality standards [85, 86]. The move to remission and maintenance has already been achieved in inflammatory disease such as rheumatoid arthritis, and the ability of the field to change the paradigm, followed by corresponding alteration to national guidance and policy, should challenge all of us to move our clinical approach forward in a way that best serves the needs of our most vulnerable patients.

**Duration of anabolic agent**

**Teriparatide**

The duration of treatment with teriparatide was initially limited by safety concerns; preclinical evidence suggested a potential association between teriparatide and osteosarcoma. Specifically, in rat studies, a dose-dependent increase in alkaline phosphatase, open epiphyses, and clinical safety of three follow-up treatments (anabolic, teriparatide, was specifically positioned for those patients with severe osteoporosis who have failed other therapies or with multiple subsequent fractures; thus a paradigm change to initial treatment with anabolics will in many cases require alterations to national guidance. Reassuringly, continuing the example of the UK, the earlier shift from BMD to absolute fracture risk based on FRAX has demonstrated that clinician led guidance, through the UK National Osteoporosis Guideline Group (produced as a response to the impractical NICE approach) has subsequently become NICE accredited and incorporated into NICE quality standards [85, 86]. The move to remission and maintenance has already been achieved in inflammatory disease such as rheumatoid arthritis, and the ability of the field to change the paradigm, followed by corresponding alteration to national guidance and policy, should challenge all of us to move our clinical approach forward in a way that best serves the needs of our most vulnerable patients.

The duration of treatment with teriparatide was initially limited by safety concerns; preclinical evidence suggested a potential association between teriparatide and osteosarcoma. Specifically, in rat studies, a dose-dependent increase in alkaline phosphatase, open epiphyses, and cardiovascular death plus heart failure and non-coronary heart disease, the incidence was 2.0% in the romosozumab group and 1.1% in the alendronate group (HR 1.7, 95% CI 1.1–2.6). A similar signal was not seen in the FRAME trial and is currently subject to ongoing post marketing surveillance studies [83].

The ESCEO working group agreed that it is difficult to differentiate between the available anabolic agents as head-to-head comparisons are limited to two studies [67, 84], hence such recommendations are outside the scope of this document. Therefore, recommendations apply to anabolics as a class rather than as individual agents.

An important consideration for the implementation of the recommendations made in this position paper, of “anabolic first” in patients at very high risk of fracture, is that the availability of any particular medication will likely be different by country and also potentially by healthcare providers within countries. For example, at the time of writing, teriparatide is widely available globally, whereas abaloparatide is not licensed in Europe. In the UK, whilst a medication may be licensed by the regulatory authorities, its use in the National Health Service may be further adjudicated by the National Institute for Health and Care Excellence (NICE). Historically, as with many healthcare systems, the available anabolic, teriparatide, was specifically positioned for those patients with severe osteoporosis who have failed other therapies or with multiple subsequent fractures; thus a paradigm change to initial treatment with anabolics will in many cases require alterations to national guidance. Reassuringly, continuing the example of the UK, the earlier shift from BMD to absolute fracture risk based on FRAX has demonstrated that clinician led guidance, through the UK National Osteoporosis Guideline Group (produced as a response to the impractical NICE approach) has subsequently become NICE accredited and incorporated into NICE quality standards [85, 86]. The move to remission and maintenance has already been achieved in inflammatory disease such as rheumatoid arthritis, and the ability of the field to change the paradigm, followed by corresponding alteration to national guidance and policy, should challenge all of us to move our clinical approach forward in a way that best serves the needs of our most vulnerable patients.

**Duration of anabolic agent**

**Teriparatide**

The duration of treatment with teriparatide was initially limited by safety concerns; preclinical evidence suggested a potential association between teriparatide and osteosarcoma. Specifically, in rat studies, a dose-dependent increase in alkaline phosphatase, open epiphyses, and cardiovascular death plus heart failure and non-coronary heart disease, the incidence was 2.0% in the romosozumab group and 1.1% in the alendronate group (HR 1.7, 95% CI 1.1–2.6). A similar signal was not seen in the FRAME trial and is currently subject to ongoing post marketing surveillance studies [83].

The duration of treatment with teriparatide was initially limited by safety concerns; preclinical evidence suggested a potential association between teriparatide and osteosarcoma. Specifically, in rat studies, a dose-dependent increase in alkaline phosphatase, open epiphyses, and cardiovascular death plus heart failure and non-coronary heart disease, the incidence was 2.0% in the romosozumab group and 1.1% in the alendronate group (HR 1.7, 95% CI 1.1–2.6). A similar signal was not seen in the FRAME trial and is currently subject to ongoing post marketing surveillance studies [83].
patients receiving raloxifene in year 2 had maintenance, but no further increase in spine BMD from year 1 (change from baseline, 7.9%), and patients receiving no active treatment had a BMD decrease of 2.5% in year 2 (change from baseline, +3.8%) [59]. Histomorphometric data support this 2-year treatment approach, demonstrating an increase in the mineralising surface available in the endocortical, periosteal and intracortical compartments [89], in addition to the trabecular network [90].

Such changes in BMD and histomorphometry are reflected by decreases in fracture risk over time: Lindsay et al., using post hoc analysis of data from the Fracture Prevention Trial, demonstrated that compared with placebo, the relative hazard for non-vertebral fragility fractures decreased by around 7% for each additional month of teriparatide treatment [91]. Similarly, in the VERO study of teriparatide versus risedronate, a continuous decrease in the rate of clinical fractures over a 2-year time period was observed in the teriparatide group [13].

To summarise, the evidence suggests that 24 months is a reasonable time frame over which to recommend teriparatide use. Few studies exist, however, testing a longer treatment duration. In one study of teriparatide versus alendronate in glucocorticoid induced osteoporosis, an increase in lumbar spine and hip BMD was observed over a 36-month period, with fewer new vertebral fractures in the teriparatide group than in patients treated with alendronate [92]. Bone turnover markers (BTMs) in the same study provide an insight into the optimal duration of teriparatide use. An increase in pro-collagen type I N propeptide (PINP) and osteocalcin (bone formation markers) was observed in the first six months of treatment, then there was a slight decrease over time. C-terminal cross-linking telopeptide of type I collagen (CTX-I), indicating bone remodelling, also increased over six months and then decreased over time almost back to baseline by 18 months [92]. This pattern of waning of the effect of teriparatide on markers of bone formation and remodelling has been observed in various different trials, and in one study inhibitors of the WNT pathway (Dickkopf-1 (DKK1) and sclerostin) were also measured over and 18-month period of teriparatide use, with an increase and then levelling off in DKK-1 over time. Therefore, changes in the regulation in bone physiology and the Wnt pathway could be part of the explanation of waning effects of teriparatide beyond 18 months–2 years [93].

Abaloparatide

The ACTIVE trial compared abaloparatide with teriparatide. As similar concerns regarding osteosarcoma risk were applied to abaloparatide (given its similar mechanism of action); the trial thus focused on the short-term use of this drug [67]. The BMD changes demonstrated a slightly greater effect of abaloparatide than teriparatide at the total hip, femoral neck and lumbar spine. When observing BTMs (CTX-I and PINP) the profiles of changes were quite different between the two drugs, a steep increase in the first three months followed by a slow decline to baseline was observed with abaloparatide, compared to a slower rise reaching a peak at 6–12 months with teriparatide. Comparing the uncoupling index (the balance between bone formation and resorption markers) between abaloparatide and teriparatide, there was only a slightly better uncoupling index at 1 month in abaloparatide but the profile was quite similar over time (18-month duration of the study). A strong association with the ratio of PINP at 3 months versus baseline with lumbar spine BMD was observed in both drugs (slightly stronger in abaloparatide) indicating that the rapid stimulation of bone formation with a high uncoupling index in the first few months of treatment is particularly important, supporting short-term use of this bone-forming agent [94].

Romosozumab

Studies evaluating BTMs in Phase 2 studies of romosozumab also show a rapid increase in markers of bone formation early in treatment, but with an uncoupling effect between formation and resorption. A rise in PINP (even steeper than observed with abaloparatide) followed by a fall back to baseline within the first 6 months of treatment is observed, alongside a sharp drop in bone resorption (CTX-I) on starting the agent, returning to baseline at 3–6 months, with both markers remaining below baseline at month 12. This suggests that after 1 year, romosozumab is a moderate bone remodelling inhibitor, rather than a potent bone-forming agent. Following transition to denosumab at 24 months, in this study, there was a further rapid decrease in bone remodelling [79]. Regarding romosozumab BMD data, this is slightly different, showing more sustained increases; there was an increase in BMD at the lumbar spine and total hip up to 24 months (with no effect at the radius). On switching to denosumab there was a further steady increase in BMD at both the lumbar spine and total hip. The majority of gains in BMD are observed in the first year, however, supporting this duration of use.

Bone turnover markers in treatment stratification

When a choice of sequential treatments is available to a clinician, it may be possible to use BTMs to aid medication decisions. Studies have demonstrated that rapid bone loss is associated with increased levels of BTMs [95]. It is also well established that elevated BTMs are associated with increased fracture risk, as demonstrated by a meta-analysis.
performed by the IFCC-IOF committee on BTMs, such that for each SD increase in PINP there was around a 23% increased risk of fracture; this was also true for CTX-I (18% increased risk per SD) [96]. However, one problem in the interpretation of BTMs in patients with osteoporosis is that patients who have recently fractured have high levels of such markers and these effects can persist for at least 4–6 months after the fracture, in many cases longer [97, 98]. Nonetheless, as previously discussed, there is substantial evidence that patients who have recently fractured are at high imminent risk of further fracture.

There is some evidence for a BMD independent predictive value of high BTMs as shown by the EPIDOS prospective study; therefore, patients with both low BMD and high BTMs are likely to be at very high risk of incident fracture [99]. However predictive capacity within a population has limitations when applied to an individual because of the substantial inter- and intra-individual variation in BTM. As discussed below, recent approaches have applied a “least significant change” approach to the use of BTM in monitoring treatment but the incorporation of BTM into prediction of fracture risk at the individual level remains a challenge.

In the future, novel biochemical markers such as high sensitivity CRP (hs-CRP) may be useful: in a recent meta-analysis of 10 studies, the RR for fracture in a comparison of the top third group to the bottom third group of hs-CRP was 1.54 (1.18–2.01), though these findings cannot be applied to an individual patient [100]. Similarly, uric acid has been shown to be predictive of fracture, with an increased serum uric acid level associated with a lower risk of fracture [101]. Higher cystatin C has been associated with higher risk of hip fractures in older women, independent of renal function [102]. Other markers may be of interest for future prospective studies including periostin, cathepsin K, osteoprotegerin (OPG), RANKL, DKK-1, sclerostin, FGF-23, Klotho, and of course miRNAs (but here we need to define the most interesting miRNAs) [103], with another novel marker, high sphingosine-1-phosphate, having been shown to be a risk factor for osteoporotic fracture independent of FRAX probability, in an Asian population [104].

Finally, reductions in BTMs in patients without a recent fragility fracture using antiresorptive therapy is known to reflect good compliance and treatment response [105]. As outlined by the ESCEO and IOF algorithm, BTMs are recommended to be checked at baseline and 3 months after starting therapy, with responders to antiresorptive considered to be those who show changes in BTMs that exceed the least significant change (56% decrease for CTX-I and 38% decrease for PINP) [43]. If at three months a decrease is not seen, it is recommended that adherence is discussed with the patient, and if they are adhering well, a treatment change may be considered, though the magnitude of BTM response may differ between therapies. In implementing such findings, further work remains to optimise the utility of BTMs in choosing between sequential therapies, though the knowledge that high levels of BTM in concert with low BMD constitutes high fracture risk is important.

**Long-term treatment: cycling of anabolic/antiresorptive therapies?**

In patients at high fracture risk, particularly younger patients, it is possible that the sequence of bone-forming agent to antiresorptive therapy might be repeated, or that shorter sequences of anabolic followed by antiresorptive therapies may be more efficacious. Cyclic administration of teriparatide alone has not been shown to increase BMD more than standard daily therapy. In a study by Cosman et al., teriparatide was given for four 3-month cycles, each followed by 3 months off, and compared to daily teriparatide for 24 months, in both alendronate naïve and women on alendronate. In the women on alendronate, cyclic teriparatide over 2 years improved BMD similarly to daily treatment in women who remained on alendronate (despite only 50% of the teriparatide dose), but in treatment naïve women there did not appear to be a BMD advantage to cyclic administration [106]. Cosman et al. further hypothesised that, because denosumab is a potent antiresorptive agent with a rapid off-effect, it might be the optimal agent to help maximise bone gains with cyclic teriparatide. In a 3-year study, 70 postmenopausal women with osteoporosis were randomised to 18 months of teriparatide followed by 18 months of denosumab (standard) or three separate 12-month cycles of 6 months of teriparatide followed by 6 months of denosumab (cyclic) [107]. The findings suggested a slight benefit of the cyclical approach at 18 months, particularly in the cortical skeletal sites (particularly the 1/3 radius), but the cyclic regimen did not demonstrate a benefit at 36 months [107]. The authors concluded that this cyclic approach could be useful in patients at the highest risk of imminent fracture, but further studies of short sequences of cyclic therapy are required, covering the different anabolic agents, with assessment of BTMs, bone structural and densitometric evaluation and assessment of fracture prevention.

The decision-making process on when (and if ever) to stop antiresorptive therapy in a patient who has received a prior anabolic agent, is often complex, and of course only minimally informed by the very limited evidence base. It is not known whether discontinuation of the second, antiresorptive agent (usually a bisphosphonate, SERM or denosumab) induces the same effect as for the second drug used alone. In a recent narrative review of available clinical trials in which therapies were discontinued and followed up for a year or more, Elbers et al. demonstrated 0.4% or lower decrease in femoral neck BMD after 1 year of

 Springer
discontinuation of therapy in both previously alendronate- and zoledronate-treated patients; hence in these patients a discontinuation of up to a year may be acceptable [108]. In the other reported agents (risedronate, ibandronate, raloxifene, teriparatide, denosumab and romosozumab) this percentage of bone loss at the femoral neck and total hip was at least 1%, with the largest decrease in BMD after discontinuation of denosumab and romosozumab, providing further support for the importance of continuation of antiresorptive agents after both agents [108].

The consensus of the group was that, if the patient remains at high risk or very high risk of fracture, it is likely that a patient will need prolonged antiresorptive therapy after anabolic treatment. However, if a patient reaches a BMD such that they are no longer at high or very high risk it may be possible to stop treatment for a short window of a maximum of a couple of years, though not if denosumab is the antiresorptive agent in use due to the risk of rebound vertebral fractures. In the case of denosumab, there is some evidence that an infusion of 5 mg zoledronate helps to reduce the rebound loss in BMD on stopping denosumab, and helps prevent vertebral fractures [109, 110]. Studies suggest that a longer duration of denosumab treatment, of more than 6 years, puts an individual at greater risk of fracture on stopping [111, 112], as does the presence of prevalent fractures [113], so supporting the need for a careful clinical approach in denosumab cessation [113, 114].

Medication adherence

It is widely recognised that patient adherence to oral bisphosphonates for osteoporosis, and the strict conditions for taking them, is poor. In a systematic review of 89 observational studies, the mean persistence of oral bisphosphonates for 6 months, 1 year and 2 years ranged from 34.8% to 71.3%, 17.7% to 74.8% and 12.9% to 72.0%, respectively, indicating that persistence and adherence reduced notably over time [115]. Across 27 different retrospective studies, non-adherence is associated with a 29% increased risk of osteoporotic fractures, and non-persistence with a 40% increased risk of osteoporotic fractures (over a 104–159-week period) [116]. Not only does poor adherence have a huge clinical burden, it also has an economic impact: a study based on Irish data demonstrated around a 50% reduction in the potential benefits (quality-adjusted life years (QALY)) gained with real-world adherence compared with patients with good adherence observed in clinical trials, and a doubling of the cost per QALY gained from these medications [117].

Poor adherence to antosteoporosis therapy has been attributed to a variety of factors, particularly when oral bisphosphonates are considered, but also in the case of parenteral therapies including anabolic agents [118]. These include condition-related factors, such as polypharmacy, older age of patients and lack of disease awareness, medication-related factors such as the frequency of dosing and side effects, health system-related factors such as care across different specialties and poor patient education, and economic factors such as poor insurance coverage [119]. A variety of studies and experts (including an IOF-ESCEO working group) have evaluated patient preferences for osteoporosis drug treatment, in order to design antosteoporosis treatments which may counter this adherence and persistence problem [120]. Whilst findings across studies are heterogeneous, and differ between countries, in general the important attributes of a treatment to encourage adherence and persistence are its effectiveness, a good side-effect profile, ease of administration, lower costs, lower treatment duration and the availability of patient-support programmes [121–126]. Wider use of treatments with preferable characteristics (which may be true of sequential treatments over antiresorptives alone) might lead to greater antosteoporosis medication adherence, though there are not yet any clinical trials to support this notion.

Cost-effectiveness of sequential treatments

In the context of spiralling fracture-related costs worldwide, health economic evaluations of treatments have become increasingly important. Such evaluations help to support priority setting in healthcare, aiding decision makers in the efficient allocation of limited healthcare resources in the ageing populations seen throughout the world. In the field of osteoporosis, the availability of newer, more expensive antiosteoporosis therapies, including abaloparatide and romosozumab, and interest in the use of sequential therapies, has brought the importance of cost-effectiveness analysis into sharper focus.

In 2021, Li et al. published an updated systematic review of the cost-effectiveness analyses of drugs for osteoporosis, using the guidelines set out by ESCEO-IOF for the conduct and reporting of economic evaluations for osteoporosis [127, 128]. This review covered studies published between 1 July 2013 and 31 December 2019, and covered the cost-effectiveness of sequential therapy in the form of a bone-forming (anabolic) agent (i.e. abaloparatide and original/branded teriparatide), followed by an antiresorptive. Three studies were identified (all in postmenopausal women in the US at increased risk of fracture), comparing abaloparatide followed by alendronate versus teriparatide followed by alendronate (Le et al., 2019) [129], sequential teriparatide/alendronate versus alendronate alone (Mori et al., 2019) [130] and sequential abaloparatide/alendronate versus teriparatide/alendronate (Hiligsmann et al., 2019) [131]. These studies used quality-adjusted life years (QALY) as their outcome.
measures as recommended, in addition to either lifetime (Mori and Hiligsmann) or 10-year time horizons (Le). These studies had mixed results (partly due to different drugs, in different age groups, with different BMD T-scores at baseline); Hiligsmann and Mori both showed that abaloparatide followed by alendronate was dominant (better outcomes, lower costs) when compared with teriparatide followed by alendronate [130, 131]. Hiligsmann also showed that abaloparatide followed by alendronate, when compared with no treatment, was cost saving or cost effective in different populations [131]. Conversely, Le et al. found that abaloparatide or teriparatide followed by alendronate was not cost effective when compared with a placebo followed by alendronate [129]; when Mori compared sequential therapy (teriparatide followed by alendronate) with alendronate alone at different ages and economic perspectives, sequential therapy was not shown to be cost effective [130]. These studies found that the high costs of abaloparatide and teriparatide largely affected incremental cost-effectiveness ratios (ICERs) when these treatments were compared with no treatment, placebo or alendronate alone. Generic/biosimilar teriparatide (if at 65–85% of the brand cost) can finely alter the balance, bringing the ICERS of sequential teriparatide/alendronate to below the willingness-to-pay (WTP) threshold of $150,000 US/QALY [130]. The systematic review commented on the limited number of studies of cost-effectiveness of sequential therapy conducted to date, particularly in very high fracture risk patients, and the need for further research in this area.

Since this review including publications up to December 31st 2019, other studies have suggested that sequential treatment may be cost effective [133–136]. Hiligsmann et al. limited their population to women with severe osteoporosis in the US (50–80 years with BMD T-score ≤ −3.5 and without a history of prior fracture, or with a T-score of −2.5 and −3.5 with a history of ≥ 1 osteoporotic fracture); sequential abaloparatide (18 months) followed by alendronate (5yrs) was compared to generic alendronate monotherapy. Sequential abaloparatide/alendronate (threshold of $150,000 US/QALY) was found to be cost effective in women ≥60 years. Söreskog et al., in a study in the UK considering a 1-year bone-forming agent, followed by antiresorptive for 4 years (versus antiresorptive monotherapy) in 70 year old women with a T-score of −2.5 and recent major osteoporotic fracture, found that the cost per QALY gained in the base-case setting was estimated at £34,584 [133]. Söreskog also modelled a Swedish population in which patients aged 74 years with a recent major osteoporotic fracture were treated with romosozumab for 12 months followed by alendronate for up to 48 months or alendronate alone with a maximum duration of 60 months. Sequential romosozumab-to-alendronate treatment was associated with 0.089 additional QALYs at an additional cost of €3002 compared to alendronate alone, resulting in an ICER of €33,732. At a Swedish reference willingness-to-pay per QALY of €60,000, the authors concluded that romosozumab-to-alendronate had a 97.9% probability of being cost effective against alendronate alone. Mori et al., studying a Japanese population of older osteoporotic women with prior vertebral fractures compared sequential teriparatide (2 years) followed by alendronate for 8 years, versus alendronate monotherapy. They found, again, that cost-effectiveness was very sensitive to treatment acquisition costs, only becoming cost effective with price discounts to teriparatide of 85%, 50%, and 15% at ages 70, 75, and 80 years, respectively, compared to the current biosimilar cost [135].

To conclude, there is emerging evidence for the cost-effectiveness of sequential treatment in osteoporosis, with bone-forming agents followed by antiresorptive agents being cost effective compared to antiresorptive alone. However, this depends upon treatment acquisition costs, and is limited to patients at very high risk of fractures; the exact fracture probability at which sequential treatment regimen is cost effective needs to be ascertained, and of course is likely to vary between healthcare systems and countries. Another recommendation for future research is to determine the maximum cost that a sequential treatment combination can hold to be cost effective within a population at a defined risk of fracture. Thus, as a result of differences in epidemiology, costs and drug prices between countries, local economic evaluation would be needed.

Clinical approach

Our ability to target patients with osteoporosis at the highest risk of fracture for the most effective antosteoporosis treatments has been identified as a clinical priority for many years and has been cited as one important strategy towards closing the osteoporosis treatment gap. We can conclude from the evidence presented above that, in patients at very high risk of fracture, sequential therapy (commencement of treatment with a bone-forming agent, followed by an antiresorptive to maintain the gains in bone mineral density), appears to be an appropriate strategy to achieve a rapid and sustained reduction in fracture risk.

We, therefore, propose a pragmatic approach to patients at very high fracture risk as outlined in Fig. 4. If an individual is found to be at very high fracture risk (which may be assessed through a variety of risk assessment modalities) they will be recommended for initial therapy with a bone-forming agent. Currently available such agents include teriparatide, abaloparatide and romosozumab (dependent on country). These should be used for the duration recommended by prescribing guidelines. It is expected that an individual’s BMD improves rapidly over this period, with a consequent reduction in fracture risk. Following this
bone-forming therapy, a consolidation period of antiresorptive therapy (such as a bisphosphonate or denosumab) is recommended, leading to either stabilisation, or gradual improvements in bone quality. Monitoring, including assessment of treatment adherence and reassessment of fracture risk, is required, to ensure that the optimal antiresorptive therapy has been chosen for the patient with minimal adverse effects, and to provide support for the achievement of maximal adherence. Longer term, given the very high fracture risk starting point for this patient population, in the vast majority of cases, consideration of the need for antiosteoporosis medication will continue to be relevant indefinitely.

**Conclusion**

We have already witnessed a paradigm shift towards early optimised treatment to achieve remission and maintenance in other areas of musculoskeletal medicine, such as in the management of inflammatory arthritis. There is now an urgent call to the osteoporosis field to alter our treatment paradigm towards anabolic therapies first in our highest fracture risk patients. Whilst there may be barriers in terms of existing national policy and availability of medications, the consensus view from this ESCEO working group strongly supported this direction as the most appropriate way in which we can make the greatest difference to the care of our most vulnerable patients.

**Funding** The ESCEO Working Group was funded by the ESCEO. The ESCEO receives unrestricted educational grants to support its educational and scientific activities from non-governmental organisations, not-for-profit organisations, non-commercial or corporate partners. The choice of topics, participants, content and agenda of the Working Groups as well as the writing, editing, submission and reviewing of the manuscript are the sole responsibility of the ESCEO, without any influence from third parties.

**Declarations**

**Conflict of interest** E.M.C. reports lecture fees and travel support from Eli Lilly, Pfizer and UCB, outside the submitted work. N.A.D. reports no conflict of interest. E.B. reports lecture fees from Amgen, outside the submitted work. M.L.B. reports honoraria from Amgen, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB, grants or speaker fees from Abiogen, Alexion, Amgen, Bruno Farmaceutici, Echolight, Eli Lilly, Kyowa Kirin, SPA, Theramex, UCB and consulting fees from Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB, outside the submitted work. E.C. EC is consultant for Diasorin, IDS, Fujirebio and Nitobo. P.Hadji. reports personal fees, consultancy, lecture fees and honoraria from AMGEN, Eli Lilly, Fresenius, Gedeon Richter, Hexal, MSD, Novartis, Roche, Stada, Theramex, UCB, outside the submitted work. P. Halbout reports no conflict...
of interest. N.C.H. reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, UCB, Kyowa Kirin, Servier, Shire, Consilient Healthcare and Internis Pharma, outside the submitted work. MKJ reports personal fees from Amgen, UCB and Besin Healthcare institutional grant support from Amgen and UCB outside the submitted work. M.H. has received research grants through institution from Amgen, Radius Health, BD, ViViV Healthcare, lecture fees from Teva and Mylan, and consulting fees from UCB outside the submitted work. M.K.J. reports no conflict of interest. J.A.K.: Nothing to declare. J.A.K. is the architect of FRAX® but has no financial interest. J.M.K. reports no conflict of interest in relation to the submitted work. O.L. reports no conflict of interest. R.M. reports no conflict of interest. A.D.P. reports lecture fees from Eli Lilly, Amgen and Gedeon Richter outside the submitted work. R.R.: Nothing to declare for the submitted work. M.R. reports no conflict of interest in relation to the submitted work. T.T. has received consultancy/speaker’s fees from Amgen, Arrow, Biogen, Chugai, Expansecs, Grunenthal, Jansen, LCA, Lilly, MSD, Nordic, Novartis, Pfizer, Sanofi, Thusaune, Theramex, TEVA et UCB and financial support or fees for research activities from: Bone Therapeutics, Chugai, UCB. F.T. reports personal fees, consultancy, lecture fees and honoraria from AMGEN, Fresenius, Gedeon-Richter, Hexal, Hologic, Kyowa-Kirin, Stadapharm, Theramex, UCB, outside the submitted work. M.V. reports no conflict of interest in relation to the submitted work. J.Y.R. has received fees for lectures or advisory boards from IBNA-Genevier, Mylan, Radius Health, Pierre Fabre, Faes Pharma, Rejunevate Biomed, Teva, Theramex, Pfizer, Mithra Pharmaceuticals, CNIEL, Dairy Research Council, Nutricia, Danone and Agenovos, and industry grants (all through institution) from IBNA-Genevier, Mylan, CNIEL, Radius Health and TRB, outside the submitted work. R.R. has received fees for lectures or advisory boards from Abiogen, Amgen, Danone, Echolight, European Milk Forum, Mithra, Nestlé, ObsEva, Pfizer Consumer Health, Radius Health, Rejunevate and Theramex. C.C. reports personal fees from AbbVie, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier and Takeda, outside the submitted work.

Ethics approval and consent to participate This narrative article contains no original data and thus issues of ethics, informed consent and patient confidentiality do not apply.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Hernlund E, Svedbom A, Ivergard M et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136
2. Cooper C, Cole ZA, Holroyd CR et al (2011) Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22:1277–1288
3. Harvey N, Dennison E, Cooper C (2010) Osteoporosis: impact on health and economics. Nat Rev Rheumatol 6:99–105
4. Kanis JA, Norton N, Harvey NC et al (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82
5. Barnsley J, Buckland G, Chan PE et al (2021) Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people. Aging Clin Exp Res 33:759–773
6. Oden A, McCloskey EV, Kanis JA et al (2015) Burden of high fracture probability worldwide: secular increases 2010–2040. Osteoporos Int 26:2243–2248
7. Harvey NC, McCloskey E (2016) Gaps and solutions in bone health: a global framework for improvement. International Osteoporosis Foundation Thematic Report
8. McClung MR (2021) Role of bone-forming agents in the management of osteoporosis. Aging Clin Exp Res 33:775–791
9. Cummings SR, Cosman F, Lewiecki EM et al (2017) Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. J Bone Miner Res 32:3–10
10. Kanis JA, Harvey NC, McCloskey E et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31:1–12
11. Kanis JA, Cooper C, Rizzoli R et al (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3–44
12. Kanis JA, Cooper C, Rizzoli R et al (2017) Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int 28:2023–2034
13. Kendler DL, Marin F, Zerbini CAF et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230–240
14. Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427
15. Barrionuevo P, Kapoor E, Asi N et al (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab 104:1623–1630
16. Díez-Pérez A, Marin F, Eriksen EF et al (2019) Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis. Bone 120:1–8
17. McCloskey EV, Borgstrom F, Cooper C et al (2021) Short time horizons for fracture prediction tools: time for a rethink. Osteoporos Int 32:1019–1025
18. Javaid MK, Harvey NC, McCloskey EV (2022) Assessment and management of imminent fracture risk in the setting of the fracture liaison service. Osteoporos Int. doi: 10.1007/s00198-021-06284-9
19. Kanis JA, Johansson H, Odén A et al (2018) Characteristics of recurrent fractures. Osteoporos Int 29:1747–1757
20. Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 339:b4229
21. Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 344:e3427
1. Bone HG, Cosman F, Miller PD et al (2018) ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 103:2949–2957
2. Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 32:198–202
3. Kanis JA, Cooper C, Rizzoli R et al (2018) Management of osteoporosis and osteoporotic fractures. J Bone Miner Res 33:1967–1979
4. Skjødt MK, Möller S, Holmberg T et al (2018) A new fracture risk assessment tool (FREM) based on public health registries. J Bone Miner Res 33:1967–1979
5. Rubin KH, Möller S, Holmberg T et al (2018) Validation of the fracture risk evaluation model (FREM) in predicting major osteoporotic fractures and hip fractures using administrative health data. Bone 147:115934
6. Möller S, Skjødt MK, Yan L et al (2022) Prediction of imminent fracture risk in Canadian women and men aged 45 years or older: external validation of the Fracture Risk Evaluation Model (FREM). Osteoporos Int 33:57–66
7. Shoback D, Rosen CJ, Black DM et al (2020) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab 105:587
8. (SIGN) SIGN (2021) Management of osteoporosis and the prevention of fragility fractures. SIGN, Edinburgh
9. Kanis JA, Johansson H, Harvey NC et al (2021) An assessment of intervention thresholds for high-fracture-risk patients applied to the NOGG guidelines: a report for the National Osteoporosis Guideline Group (NOGG). Osteoporos Int 32:1951–1960
10. Ferrari S, Lippuner K, Lamy O et al (2020) Recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO). Swiss Med Wkly 150:w20352
11. Cooper CJM, Elliott M, Stephens D et al (2020) UK consensus guideline on the management of patients at low, high, and very high risk of osteoporotic fracture. www.guidelines.co.uk. MGP Guidelines
12. Kanis JA (2007) Assessment of osteoporosis at the primary health care level. World Health Organization, Geneva
13. Kanis JA, Johansson H, Harvey NC et al (2018) A brief history of FRAX. Arch Osteoporos 3:118
14. Kanis JA, Johansson H, Oden A et al (2014) Worldwide uptake of FRAX. Arch Osteoporos 9:166
15. Kanis JA, Harvey NC, Cooper C et al (2016) A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11:25
16. Kanis JA, Harvey NC, Johansson H et al (2020) A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res 32:187–196
17. Lorenzoni M, Branco J, Brandi ML et al (2019) Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment, and follow-up of treatment for osteoporosis. Adv Ther. https://doi.org/10.1007/s12325-019-01063-9
18. McCloskey E, Kanis JA, Johansson H et al (2015) FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK. Osteoporos Int 26:2091–2099
19. Johansson H, Siggeisrdottir K, Harvey NC et al (2017) Imminent risk of fracture after fracture. Osteoporos Int 28:775–780
20. Johnell O, Kanis JA, Oden A et al (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175–179
21. Ahmed LA, Center JR, Bjørnerem Å et al (2013) Progressively increasing fracture risk with advancing age after initial incident fragility fracture: the Tromsø study. J Bone Miner Res 28:2214–2221
22. Kanis JA, Johansson H, Harvey NC et al (2020) Adjusting conventional FRAX estimates of fracture probability according to the regimen of sentinel fractures. Osteoporos Int 31:1817–1828
23. Kanis JA, Johansson H, Harvey NC et al (2021) The use of 2-, 5-, and 10-year probabilities to characterize fracture risk after a recent sentinel fracture. Osteoporos Int 32:47–54
24. Leder BZ, Tsai JN, Neer RM et al (2016) Response to therapy with teriparatide, denosumab, or both in postmenopausal women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial. J Clin Densitom 19:346–351
25. Bone HG, Cosman F, Miller PD et al (2018) ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 103:2949–2957
26. Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 32:198–202
27. Kanis JA, Cooper C, Rizzoli R et al (2018) Review of the guideline of the American College of Physicians on the treatment of osteoporosis. Osteoporos Int 29:1505–1510
28. Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905–916
29. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441
results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 24:726–736
60. Kaufman JM (2021) Management of osteoporosis in older men. Aging Clin Exp Res 33:1439–1452
61. Finkelstein JS, Hayes A, Hunzelman JL et al (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216–1226
62. Finkelstein JS, Wyland JJ, Lee H et al (2010) Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 95:1838–1845
63. Cosman F, Eriksen EF, Recknor C et al (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis. J Bone Miner Res 26:503–511
64. Tsai JN, Uihlein AV, Lee H et al (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382:50–56
65. Leder BZ, Tsai JN, Uihlein AV et al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386:1147–1155
66. Hattersley G, Dean T, Corbin BA et al (2016) Binding selectivity of abaloparatide for PTH-Type-1-receptor conformations and effects on downstream signaling. Endocrinology 157:141–149
67. Miller PD, Hattersley G, Riis BJ et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomised clinical trial. JAMA 316:722–733
68. Cosman F, Miller PD, Williams GC et al (2017) Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVEExtend Trial. Mayo Clin Proc 92:200–210
69. Reginster J-Y, Hattersley G, Williams GC et al (2018) Abaloparatide is an effective treatment option for postmenopausal osteoporosis: review of the number needed to treat compared with teriparatide. Calcif Tissue Int 103:540–545
70. Estell EG, Rosen CJ (2021) Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis. Nat Rev Endocrinol 17:31–46
71. McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412–420
72. Padhi D, Jang G, Stouch B et al (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19–26
73. Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543
74. Cosman F, Crittenden DB, Ferrari S et al (2018) Romosozumab FRAME study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. J Bone Miner Res 33:1407–1416
75. McCluskey EV, Johansson H, Harvey NC et al (2021) Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study. Osteoporos Int 32:1601–1608
76. Lewiecki EM, Dinavahi RV, Lazaretti-Castro M et al (2019) One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME Extension Study. J Bone Miner Res 34:419–428
77. Cosman F, Crittenden DB, Ferrari S et al (2018) FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res 33:1219–1226
78. Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513–523
79. McClung MR, Brown JP, Diez-Perez A et al (2018) Effects of 24 months of treatment with rosmosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a Randomized, Double-Blind, Phase 2, Parallel Group Study. J Bone Miner Res 33:1397–1406
80. McClung MR, Bolognese MA, Brown JP et al (2020) A single dose of zolendronate preserves bone mineral density for up to 2 years after a second course of rosmosozumab. Osteoporos Int 31:2231–2241
81. Harvey NC, Kanis JA, Odén A et al (2015) Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX. Osteoporos Int 26:2347–2353
82. Harvey NC, Kanis JA, Odén A et al (2015) FRAX and the effect of teriparatide on vertebral and non-vertebral fracture. Osteoporos Int 26:2677–2684
83. Fuggle NR, Cooper C, Harvey NC et al (2020) Assessment of cardiovascular safety of anti-osteoporosis drugs. Drugs 80:1537–1552
84. Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy; a randomised, open-label, phase 3 trial. Lancet 390:1585–1594
85. Compston J, Cooper A, Cooper C et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43
86. Harvey NC, McCluskey E, Kanis JA et al (2018) Cost-effective but clinically inappropriate: new NICE intervention thresholds in osteoporosis (Technology Appraisal 464). Osteoporos Int 29:1511–1513
87. Vahle JL, Sato M, Long GG et al (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 30:312–321
88. Gilsenan A, Midkiff K, Harris D et al (2021) Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study. J Bone Miner Res 36:244–251
89. Ma YL, Zeng QQ, Chiang AY et al (2014) Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. Bone 59:139–147
90. Dempster DW, Roschger P, Misof BM et al (2016) Differential effects of teriparatide and zoledronic acid on bone mineralization density distribution at 6 and 24 months in the SHOTZ Study. J Bone Miner Res 31:1527–1535
91. Lindsay R, Miller P, Pohl G et al (2009) Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int 20:943–948
92. Saag KG, Zanchetta JR, Devogelaer JP et al (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346–3355
93. Gatti D, Biagini E, Oddola A et al (2017) The waxing of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab 96:1555–1569
94. Eastell R, Mitlak BH, Wang Y et al (2019) Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE. Osteoporos Int 30:667–673
132. Hiligsmann M, Williams SA, Fitzpatrick LA (2020) Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: a US payer perspective. Semin Arthritis Rheum 50:394–400

133. Söreskog E, Borgström F, Lindberg I et al (2021) A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis. Osteoporos Int 32:1301–1311

134. Söreskog E, Lindberg I, Kanis JA et al (2021) Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden. Osteoporos Int 32:585–594

135. Mori T, Crandall CJ, Fujii T et al (2021) Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan. Arch Osteoporos 16:72

136. Mori T, Crandall CJ, Fuji T et al (2021) Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan. Arch Osteoporos 16:113

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Elizabeth M. Curtis1 · Jean-Yves Reginster2,3 · Nasser Al-Daghri4 · Emmanuel Biver5 · Maria Luisa Brandi6 · Etienne Cavalier7 · Peyman Hadji8,9 · Philippe Halbout10 · Nicholas C. Harvey1,11 · Mickaël Hiligsmann12 · M. Kassim Javaid13 · John A. Kanis14,15 · Jean-Marc Kaufman16 · Olivier Lamy17 · Radmila Matijevic18,19 · Adolfo Diez Perez20 · Régis Pierre Radermecker21 · Mário Miguel Rosa22 · Thierry Thomas23,24 · Friederike Thomasius8 · Mila Vlaskovska25 · René Rizzoli1 · Cyrus Cooper1,11,26

1 MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK
2 WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liège, Belgium
3 Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart Tilman B23, 4000 Liège, Belgium
4 Biochemistry Department, College of Science, King Saud University, 11451 Riyadh, Kingdom of Saudi Arabia
5 Division of Bone Diseases, Department of Medicine, Faculty of Medicine, Geneva University Hospitals, University of Geneva, Geneva, Switzerland
6 F.I.R.M.O, Italian Foundation for the Research on Bone Diseases, Florence, Italy
7 Department of Clinical Chemistry, University of Liège, CHU de Liège, Liège, Belgium
8 Center of Bone Health, Frankfurt, Germany
9 Philipps-University of Marburg, Marburg, Germany
10 International Osteoporosis Foundation, Nyon, Switzerland
11 NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK
12 Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands
13 NDORMS, University of Oxford, Windmill Road, Oxford, UK
14 Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia
15 Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK
16 Department of Endocrinology, Ghent University Hospital, Gent, Belgium
17 University of Lausanne, UNIL, CHUV, Lausanne, Switzerland
18 Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
19 Clinical Center of Vojvodina, Clinic for Orthopedic Surgery, Novi Sad, Serbia
20 Department of Internal Medicine, Hospital del Mar-IMIM, Autonomous University of Barcelona and CIBERFES, Instituto Carlos III, Madrid, Spain
21 Department of Diabetes, Nutrition and Metabolic Disorders, Clinical Pharmacology, University of Liège, CHU de Liège, Liège, Belgium
22 Faculty of Medicine, University of Lisboa, Lisbon, Portugal
23 Department of Rheumatology, Hôpital Nord, CHU Saint-Etienne, Saint-Etienne, France
24 INSERM U1059, Université de Lyon, Université Jean Monnet, Saint-Etienne, France
25 Medical Faculty, Department of Pharmacology and Toxicology, Medical University Sofia, Sofia, Bulgaria
26 NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK